Ushakova, Olga; Sokolovskaya, Vera; Morozova, Alla; Valeeva, Farida; Zanozina, Olga; Sazonova, Olga; Zhadanova, Elena; Starceva, Maria; Kazakova, Elena; Saifullina, Marina; Shapiro, Irina; Tarasov, Alexander; Al-Tayar, Bassam; Starkova, Ninella
Clinical therapeutics; 2007 Nov;29(11):2374-84. PMID: 18158078
Department of Prophylactic Medicine, Post-graduate Medical Education Institute, Khabarovsk, Russia.
Abstract
Modern premixed insulins offer a flexible approach to the initiation of insulin therapy in patients with poorly controlled type 2 diabetes. A disadvantage of twice-daily regimens of biphasic insulin aspart 30 (BIAsp 30) is that lunchtime control (when no insulin is administered) can be suboptimal. Therefore, it is possible that administering BIAsp 30 thrice daily might further optimize glycemic control and offer an option for patients in whom metformin (MET) is contraindicated.